title: Less weight or more hype with rimonabant?
abstract: Rimonabant (Acomplia - Sanofi-Aventis) has been licensed in the UK since June 2006 for the treatment of obese and certain overweight adults. Advertisements claim the drug has beneficial effects on "cardiometabolic risk factors", and that "an estimated 50% of the effects. . .on cardiometabolic risk factors are beyond those expected from weight loss alone". Here we review the role of rimonabant in managing patients with obesity.
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D016527:Drug Costs; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D000077285:Rimonabant; D012307:Risk Factors; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects
chemical_list: D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant